-- 加拿大帝国商业银行（CIBC）表示，周四公布国内生产总值（GDP）数据后，加拿大国债收益率有所下降，部分抵消了前一天因市场预期加拿大央行鹰派言论而出现的上涨行情。 该行指出，加拿大经济增长似乎在第一季度有所复苏，但远未达到最佳状态，3月份的初步数据显示，季度末经济增长可能再次停滞。GDP增长和就业持续不平衡表明，经济中的闲置产能尚未被消化，并将继续抵消能源价格上涨的影响，从而抑制核心通胀指标。 因此，CIBC仍然认为，加拿大央行可以忽略当前通胀率的飙升，并在今年维持利率不变。 2月份的月度GDP数据显示环比增长0.2%，与市场普遍预期一致。3月份GDP的初步数据显示，该月GDP与上月持平。 加拿大帝国商业银行（CIBC）表示，尽管第一季度经济增长似乎接近加拿大央行货币政策报告的预测，但3月份再次出现的停滞令人担忧，因为这会影响春季的经济动能。消费者支出似乎再次放缓，考虑到汽油价格上涨带来的压力以及劳动力市场依然疲软，这种情况是可以理解的。 该行仍然认为，即使能源价格上涨的影响在某些领域显现，加拿大经济仍有足够的闲置产能来维持核心通胀指标的温和水平，这将使加拿大央行能够将利率维持在2026年之前不变。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN